Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Crossref DOI link: https://doi.org/10.1007/s12325-016-0353-2
Published Online: 2016-06-01
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Krueger, James G.
Kircik, Leon
Hougeir, Firas
Friedman, Adam
You, Xiaojun
Lucas, Nisha
Greenberg, Steven J.
Sweetser, Marianne
Castro-Borrero, Wanda
McCroskery, Peter
Elkins, Jacob
Funding for this research was provided by:
Biogen
AbbVie Biotherapeutics Inc